<img src="https://ml.globenewswire.com/Resource/Download/7062c765-82cc-4ba2-ba1f-4b1396b9b052?size=2" nborder="0" align="left" hspace="5" vspace="5" title="immulogo.jpg" alt="Immunovant Inc."/>DURHAM, N.C., May 11, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026. To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this <a href="https://www.globenewswire.com/Tracker?data=31zG19r7cIMfj4dLYa2GZcGMMVJsXYupQU1EBnWoUGjyCCPLsUNxKByg_NmSzeKyYmdbDDT7WWdUP9lnNgoxuk0jgWO8_LQhkplfRU_l39uVq9qiz0BoEEdRENWQNiSNhHN3rpKa5SEWUntAYYmtv8prYFY6lhialEQWn6vKOLw=" rel="nofollow" target="_blank" title="">registration link</a>. The presentation and webcast details will also be available under “News &amp; Events” in the Investors section of the Immunovant website at <a href="https://www.globenewswire.com/Tracker?data=fPVWoQB6ciGKFW1hjQjNeeRAZf6FEA1gOiCDfsJNT9jUjW_ccpiG_xGPwefD52C6Y-pjHwGZKpa01SiI1qWC8fk4Gc8MuW1D1lCg4z3fbnkgJHsj2KWEf2FVom0sd3dZfOX4aOyEic00fJ_YwpvRiUNUYlcgCo5amU74ib6s5s49QU8LYVXWyyGHm8F-B_Loq8XGNyTE64DuEyqAf2Lkm8ZMiaVHzOqJAig1-KlQv28EU2-jJj2nFvXEt3Y2_CrePWS25NMAyqX80yhAFRqELANr2bWKCzWm7aVUnRBx3mheeBg93AA2hq41s0VIKxj8KxSIh41WbC-GFUIg_UamoZg3YANCF4PqJtC-4_VLAI7Uf2Jx-mJKuqJRoiPys1wM4XCdoNFg70eSNmS5l5Fsr6QSx0n1AHpDhXHUL-r2ZeqibSKxufdcG503-42EnJLS0EPxxXwyq1ckdEtT1bOpqA==" rel="nofollow" target="_blank" title="">https://www.immunovant.com/investors/news-events/ir-calendar</a>. The archived webcast will be available on Immunovant’s website after the conference call. About Immunovant  Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit <a href="https://www.globenewswire.com/Tracker?data=dvtyP3twgOTCMA-CetV6pXsI4C9Xm8YGaAKulRT1eXohEqj4CEWOGDltuHtEJqPCvt6R8-3w-DsyAcR9KQqTp824aQB-cIjGtuPhIYZJumou2nSGOHAU3kz5D_9F_YBUntExsfsURQNBeClLJccL_J-v21FRie2iMn2lBBEbxC3h7Lp7AyVf-euwAThbhKXbWpsyuWtBA7xiK_brXRR7z-3ebxAcD5Vs4_sd4a7v4T_N7qOuXGlfTO-ibbCDA4-LNXziCiBf9-vk7JbPwy6zqf4bbntRx7AtQwZf0-GVPwXr8wcTzxpf1yxdAPjtkoSQBGPCVLtYZhirvAINITKI_E40qp92m1CuEkT7s0rVXJwXbtwQ3xx7NPvwzTMl9px1WVB3D6q5ou6XMYoBF_lGL1qtOlJjDcH6hm1G5zQNmBs=" rel="nofollow" target="_blank" title="immunovant.com">immunovant.com</a>.  Contacts:  Investors  Keyur Parekh  keyur.parekh@roivant.com   Media  Stephanie Lee  stephanie.lee@roivant.com  <img alt="" src='https://ml.globenewswire.com/media/OWNkZmNiMTUtYjJkMy00ZWUxLThiNTYtN2NhNmE4N2E0OThlLTExMzc0MTUtMjAyNi0wNS0xMS1lbg==/tiny/Immunovant-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn